Ratings Medigene AG

Equities

MDG1

DE000A1X3W00

Market Closed - Xetra Other stock markets 11:36:24 2024-04-26 am EDT			5-day change	1st Jan Change
1.505 ^EUR	-5.64%		-21.61%	-1.31%

Apr. 25	Medigene AG Presents Streamlined 6-Day, High Stemness Tcr-T Therapy Production Process	CI
Apr. 08	Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024	CI

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
The average consensus view of analysts covering the stock has deteriorated over the past four months.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MEDIGENE AG	-1.31%	39.46M	-
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B	B+
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B	B+
ARGENX SE	+1.69%	22.15B	B
BIONTECH SE	-17.37%	21.02B	B+
GENMAB A/S	-9.30%	18.15B	A-
WUXI APPTEC CO., LTD.	-41.01%	16.73B	A-
BEIGENE, LTD.	-14.85%	16.05B	B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B	C+
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes